Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.

Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty AJ, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2016 Dec;76(18):1737-1757. Review.

PMID:
27909995
2.

The role of solithromycin in the management of bacterial community-acquired pneumonia.

Van Bambeke F, Tulkens PM.

Expert Rev Anti Infect Ther. 2016;14(3):311-24. doi: 10.1586/14787210.2016.1138857. Epub 2016 Feb 5. Review.

PMID:
26848612
3.

Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).

Barrera CM, Mykietiuk A, Metev H, Nitu MF, Karimjee N, Doreski PA, Mitha I, Tanaseanu CM, Molina JM, Antonovsky Y, Van Rensburg DJ, Rowe BH, Flores-Figueroa J, Rewerska B, Clark K, Keedy K, Sheets A, Scott D, Horwith G, Das AF, Jamieson B, Fernandes P, Oldach D; SOLITAIRE-ORAL Pneumonia Team.

Lancet Infect Dis. 2016 Apr;16(4):421-30. doi: 10.1016/S1473-3099(16)00017-7. Epub 2016 Feb 5.

PMID:
26852726
4.

Solithromycin: A novel ketolide antibiotic.

Buege MJ, Brown JE, Aitken SL.

Am J Health Syst Pharm. 2017 Jun 15;74(12):875-887. doi: 10.2146/ajhp160934. Epub 2017 Apr 21. Review.

PMID:
28432048
5.

Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.

Donald BJ, Surani S, Deol HS, Mbadugha UJ, Udeani G.

Drug Des Devel Ther. 2017 Dec 13;11:3559-3566. doi: 10.2147/DDDT.S119545. eCollection 2017. Review.

6.

SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.

File TM Jr, Rewerska B, Vucinic-Mihailovic V, Gonong JRV, Das AF, Keedy K, Taylor D, Sheets A, Fernandes P, Oldach D, Jamieson BD.

Clin Infect Dis. 2016 Oct 15;63(8):1007-1016. doi: 10.1093/cid/ciw490. Epub 2016 Jul 22.

PMID:
27448679
7.

Solithromycin for the treatment of community-acquired bacterial pneumonia.

Viasus D, Ramos O, Ramos L, Simonetti AF, CarratalĂ  J.

Expert Rev Respir Med. 2017 Jan;11(1):5-12. doi: 10.1080/17476348.2017.1249852. Epub 2016 Oct 31.

PMID:
27753516
8.

Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.

Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, Jamieson BD, Fernandes P.

Antimicrob Agents Chemother. 2013 Jun;57(6):2526-34. doi: 10.1128/AAC.00197-13. Epub 2013 Mar 18.

9.

Antimicrobial activity of solithromycin and levofloxacin against a murine pneumonia mixed-infection model caused by Streptococcus pneumoniae and anaerobic bacteria.

Kato H, Yamagishi Y, Hagihara M, Yokoyama Y, Suematsu H, Asai N, Koizumi Y, Mikamo H.

J Infect Chemother. 2019 Apr;25(4):311-313. doi: 10.1016/j.jiac.2018.09.003. Epub 2018 Oct 2.

PMID:
30287186
10.

Results from the Solithromycin International Surveillance Program (2014).

Farrell DJ, Flamm RK, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2016 May 23;60(6):3662-8. doi: 10.1128/AAC.00185-16. Print 2016 Jun.

11.

The ketolides: a critical review.

Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ.

Drugs. 2002;62(12):1771-804. Review.

PMID:
12149046
12.

Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniae.

Figueira M, Fernandes P, Pelton SI.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5533-8. doi: 10.1128/AAC.00863-16. Print 2016 Sep.

13.

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012.

Farrell DJ, Mendes RE, Jones RN.

Antimicrob Agents Chemother. 2015 Apr;59(4):2432-4. doi: 10.1128/AAC.04568-14. Epub 2015 Jan 20.

14.

Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.

Shi J, Montay G, Bhargava VO.

Clin Pharmacokinet. 2005;44(9):915-34. Review.

PMID:
16122280
15.

The solithromycin journey-It is all in the chemistry.

Fernandes P, Martens E, Bertrand D, Pereira D.

Bioorg Med Chem. 2016 Dec 15;24(24):6420-6428. doi: 10.1016/j.bmc.2016.08.035. Epub 2016 Aug 22. Review.

16.

Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.

Zhanel GG, Johanson C, Hisanaga T, Mendoza C, Laing N, Noreddin A, Wierzbowski A, Hoban DJ.

J Antimicrob Chemother. 2004 Dec;54(6):1072-7. Epub 2004 Nov 5.

PMID:
15531596
17.

The wobbly status of ketolides: where do we stand?

Georgopapadakou NH.

Expert Opin Investig Drugs. 2014 Oct;23(10):1313-9. doi: 10.1517/13543784.2014.954036. Epub 2014 Aug 25.

PMID:
25154307
18.

Metabolism, Excretion, and Mass Balance of Solithromycin in Humans.

MacLauchlin C, Schneider SE, Keedy K, Fernandes P, Jamieson BD.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e01474-17. doi: 10.1128/AAC.01474-17. Print 2018 May.

20.

Supplemental Content

Support Center